Polaris Group (6550.TW)

TWD 38.0

(-5.59%)

Operating Expenses Summary of Polaris Group

  • Polaris Group's latest annual operating expenses in 2023 was -3.06 Million TWD , up 68.28% from previous year.
  • Polaris Group's latest quarterly operating expenses in 2024 Q2 was 570.29 Million TWD , down -100.82% from previous quarter.
  • Polaris Group reported a annual operating expenses of 1.01 Billion TWD in annual operating expenses 2022, up 74.73% from previous year.
  • Polaris Group reported a annual operating expenses of 581.29 Million TWD in annual operating expenses 2021, up 6.23% from previous year.
  • Polaris Group reported a quarterly operating expenses of 570.29 Million TWD for 2024 Q2, down -100.82% from previous quarter.
  • Polaris Group reported a quarterly operating expenses of 563.45 Million TWD for 2023 Q4, up 22.45% from previous quarter.

Annual Operating Expenses Chart of Polaris Group (2023 - 2016)

Historical Annual Operating Expenses of Polaris Group (2023 - 2016)

Year Operating Expenses Operating Expenses Growth
2023 -3.06 Million TWD 68.28%
2022 1.01 Billion TWD 74.73%
2021 581.29 Million TWD 6.23%
2020 547.21 Million TWD -16.69%
2019 656.87 Million TWD -27.27%
2018 903.2 Million TWD 23.74%
2017 729.94 Million TWD -10.98%
2016 820.02 Million TWD 0.0%

Peer Operating Expenses Comparison of Polaris Group

Name Operating Expenses Operating Expenses Difference
Apex Biotechnology Corp. 389.4 Million TWD 100.787%
Sinphar Pharmaceutical Co.,Ltd. 807.86 Million TWD 100.379%
Panion & Bf Biotech Inc. 817.56 Million TWD 100.375%
Chunghwa Chemical Synthesis & Biotech Co., Ltd. 437.58 Million TWD 100.7%
GenMont Biotech Incorporation 204.2 Million TWD 101.501%
Abnova (Taiwan) Corporation 126.72 Million TWD 102.419%
Adimmune Corporation 1.13 Billion TWD 100.27%
Tanvex BioPharma, Inc. 2.16 Billion TWD 100.142%
Energenesis Biomedical CO.,LTD. 267.06 Million TWD 101.148%
UnicoCell Biomed Co., Ltd. 17.89 Million TWD 117.126%
PELL Bio-Med Technology Co. Ltd. 385.1 Million TWD 100.796%